{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 373,
  "pageCount": 415,
  "prevPage": 372,
  "nextPage": 374,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses direct quotes to frame the expert's skepticism and clinical concerns about the drug's safety profile.",
  "elementsJson": [
    "paragraph",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/373",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-373",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "I think 30% of drug patients, treated patients actually developed edema, while 10% of the placebo developed edema, which is 1 in 10 in the placebo group developed edema. I'm more worried about the edema.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c4-6f01e213cac1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The endocrinologist indicated significant concern about edema-induced cardiac risk, as well as diabetes, to the point that he has asked Soleno for an answer; and plans baseline cardiac evaluations, which we presume would involved an echocardiogram",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f157367c-ef0a-4d1e-8da9-11e9966cc09f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.56
      },
      "kind": "quote",
      "text": "I'm more concerned about the edema than the hyperglycemia - it's easier to monitor for the hyperglycemia than for the edema. And so that's been a question I've asked them: how do they clinically evaluate for edema if you're not going to be seeing the patient all the time? Are you relying on reports by the parents, etc.? If you actually look at the data, I think 30% of drug patients, treated patients actually developed edema, while 10% of the placebo developed edema, which is 1 in 10 in the placebo group developed edema. I'm more worried about the edema.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39a134f1-25af-473b-9c96-5d7796c90dce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.75
      },
      "kind": "quote",
      "text": "My concern is how do we clinically monitor it? I personally am doing baseline cardiac evaluations on these patients to ensure that optimal cardiac health, etc., in case they do develop edema, which can put strain on the cardiac function. But that's something that we have to monitor for by doing maybe weekly weights, relying on the parents, etc. There are ways of dealing with it. You can reduce the dose, you can stop drugs, you can put them on a diuretic. But the proof is going to be when we start treating these patients and seeing what happens. But that's really the number one for me, the edema. And then the hyperglycemia...we just have to wait and see what happens.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86905b90-f466-48b2-a025-fcf8229ef60a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“I'm more concerned about the edema than the hyperglycemia...it's easier to monitor for the hyperglycemia than for the edema...that's been a question I've asked them: how do they clinically evaluate for edema if you're not going to be seeing the patient all the time?...I think 30% of drug patients, treated patients actually developed edema... I'm more worried about the edema”; “I personally am doing baseline cardiac evaluations on these patients...in case they do develop edema, which can put strain on the cardiac function... the proof is going to be when we start treating these patients and seeing what happens...we just have to wait and see what happens.” — Division Chief for pediatric endocrinology at a major NE academic center",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c4-729f5d4cd0ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22868253-5c0e-4acc-a8f5-cfbcaaba79ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}